Apellis Pharmaceuticals (APLS) Receivables - Net (2021 - 2025)
Apellis Pharmaceuticals has reported Receivables - Net over the past 5 years, most recently at $366.2 million for Q4 2025.
- Quarterly results put Receivables - Net at $366.2 million for Q4 2025, up 38.24% from a year ago — trailing twelve months through Dec 2025 was $366.2 million (up 38.24% YoY), and the annual figure for FY2025 was $366.2 million, up 38.24%.
- Receivables - Net for Q4 2025 was $366.2 million at Apellis Pharmaceuticals, up from $345.5 million in the prior quarter.
- Over the last five years, Receivables - Net for APLS hit a ceiling of $366.2 million in Q4 2025 and a floor of $719000.0 in Q2 2021.
- Median Receivables - Net over the past 5 years was $169.3 million (2023), compared with a mean of $149.4 million.
- Biggest five-year swings in Receivables - Net: surged 2580.52% in 2023 and later decreased 29.66% in 2025.
- Apellis Pharmaceuticals' Receivables - Net stood at $10.1 million in 2021, then fell by 23.76% to $7.7 million in 2022, then surged by 2580.52% to $206.4 million in 2023, then increased by 28.36% to $264.9 million in 2024, then skyrocketed by 38.24% to $366.2 million in 2025.
- The last three reported values for Receivables - Net were $366.2 million (Q4 2025), $345.5 million (Q3 2025), and $214.1 million (Q2 2025) per Business Quant data.